Compound medicine for treating gastroenteric tumor

Abstract

The invention discloses a compound medicine for treating gastroenteric tumor. The compound medicine is prepared from the following traditional Chinese medicinal raw materials in parts by weight: 3 to 5 parts of radix ranunculi ternate, 4 to 6 parts of fructus polygoni orientalis, 3 to 5 parts of myrrh, 3 to 5 parts of herba rabdosiae, 3 to 5 parts of indigo naturalis, 5 to 8 parts of radix sophorae tonkinensis, 2 to 4 parts of radix platycodonis, 2 to 4 parts of cortex moutan, 6 to 10 parts of radix astragali, 6 to 8 parts of radix pseudostellariae, 1 to 3 parts of ganoderma, 5 to 8 parts of donkey-hide gelatin, 2 to 4 parts of rhizoma imperatae, 2 to 4 parts of corn stigma, 2 to 4 parts of herba abri, 2 to 3 parts of ossa draconis, 2 to 3 parts of herba lysimachiae, 2 to 3 parts of semen plantaginis, 2 to 3 parts of chingma abutilon seed, 2 to 4 parts of medulla junci, 1 to 3 parts of myrmeleontid larva and 2 to 4 parts of pollen typhae. According to the theories that traditional Chinese medicines have efficacies of strengthening and consolidating body resistance and promoting blood circulation to remove blood stasis, the compound medicine has the effects of tonifying the liver and kidney, reinforcing Qi and nourishing Yin, clearing away heat and toxic materials, and dissolving and relieving swelling, can be used for treating the gastroenteric tumor, treats both manifestation and root cause of disease, and is good in curative effect and quick in result.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, in particular to a compound medicine for treating gastrointestinal tumors. Background technique [0002] Gastrointestinal tumors are benign and malignant tumors that occur in the stomach, small intestine, and large intestine. Clinical manifestations vary according to the nature and location of tumor occurrence. In general, benign tumors can be asymptomatic or have very mild symptoms. Some malignant tumors have no obvious symptoms in the early stage, which affects diagnosis, treatment and prognosis. Among gastrointestinal tumors, the incidence of tumors in the small intestine is lower than that in the esophagus, stomach, and large intestine. [0003] Manifested as severe abdominal pain, intestinal bleeding, intestinal obstruction, abdominal mass and weight loss. The symptoms of malignant tumors are more and more severe, while the symptoms of benign tumors are mild or asymp...

AI Technical Summary

Problems solved by technology

In addition to conventional chemotherapy drugs, humanized antibody drugs, molecular targeted drugs, and new targeted carrier drugs are all very expensive